Chimeric Antigen Receptor T Cell Therapy For Solid Tumors.

Authors

Jingmei Hsu
Yang Yang
Mia Gergis
Xia Bi
Dongni Yi
Usama Gergis MD, MBA, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

12-15-2022

Abstract

Chimeric antigen receptor T (CAR T) cell therapy has revolutionized the management of lymphoid malignancies. However, it is still in its early phase and is facing many obstacles in solid tumors. Therapeutic challenges in solid tumor lead to tumor target diversification and drive new innovations for the improvement of clinical efficacy. This review showcases early clinical works and sheds light on the most notable successes, drawbacks, and strategies employed to allow CAR T therapy to go full speed ahead.

Volume

15

Issue

3

First Page

94

Last Page

99

ISSN

2589-0646

Published In/Presented At

Hsu, J., Yang, Y., Gergis, M., Bi, X., Yi, D., & Gergis, U. (2022). Chimeric Antigen Receptor T Cell Therapy For Solid Tumors. Hematology/oncology and stem cell therapy, 15(3), 94–99. https://doi.org/10.56875/2589-0646.1028

Disciplines

Medicine and Health Sciences

PubMedID

36537910

Department(s)

Department of Medicine, Lehigh Valley Topper Cancer Institute

Document Type

Article